## Management of ASCUS with High-Risk HPV **Key Point:** ASCUS (atypical squamous cells of undetermined significance) combined with **high-risk HPV positivity (HPV-16)** mandates immediate colposcopy. HPV-16 is an oncogenic type with significant risk for cervical intraepithelial neoplasia (CIN) and cancer. ### Triage Algorithm for ASCUS ```mermaid flowchart TD A[ASCUS on Pap smear]:::outcome --> B{HPV reflex test}:::decision B -->|HPV-negative| C[Routine screening in 3 years]:::action B -->|HPV-positive| D{High-risk type?}:::decision D -->|HPV-16/18| E[Immediate colposcopy]:::action D -->|Other high-risk| F[Colposcopy or repeat cytology]:::action E --> G[Biopsy if abnormal]:::action G --> H{CIN grade?}:::decision H -->|CIN1| I[Observation or treatment]:::outcome H -->|CIN2/3| J[Excisional treatment]:::urgent ``` **High-Yield:** The **HPV-16 + ASCUS combination** is a high-risk scenario: - HPV-16 is the most oncogenic type (accounts for ~50% of cervical cancers) - ASCUS with HPV-16 has ~25–30% risk of underlying CIN2/3 - Colposcopy is mandatory to exclude dysplasia ### Management Pathways by HPV Status | Scenario | Next Step | Rationale | |----------|-----------|----------| | ASCUS + HPV-negative | Routine screening (3 years) | Low cancer risk; HPV clearance likely | | ASCUS + HPV-16/18 | Immediate colposcopy | High cancer risk; need tissue diagnosis | | ASCUS + other high-risk HPV | Colposcopy or repeat cytology | Intermediate risk; individualize | | ASCUS + unknown HPV status | HPV reflex test | Stratify risk | **Clinical Pearl:** HPV-16 is present in ~50% of cervical cancers and has the highest malignant potential. Any cytologic abnormality (even ASCUS) with HPV-16 requires colposcopic evaluation. **Mnemonic: ASCUS-16** — **A**SCUS + **S**trong oncogenic **C**irculation of **U**ndetermined **S**ignificance → **16** (HPV-16) → **Colposcopy NOW**.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.